0000000000549129

AUTHOR

Knight J

showing 2 related works from this author

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes.

2006

Contains fulltext : 35205.pdf (Publisher’s version ) (Closed access) Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, starting in early childhood and persisting into adulthood in the majority of cases. Family and twin studies have demonstrated the importance of genetic factors and candidate gene association studies have identified several loci that exert small but significant effects on ADHD. To provide further clarification of reported associations and identify novel associated genes, we examined 1,038 single-nucleotide polymorphisms (SNPs) spanning 51 candidate genes involved in the regulation of neurotransmitter pathways, particularly dopamine, nor…

Candidate geneGenetics and epigenetic pathways of disease [NCMLS 6]MedizinReceptors NicotinicTryptophan HydroxylaseNeuroinformatics [DCN 3]0302 clinical medicinePerception and Action [DCN 1]Determinants in Health and Disease [EBP 1]ChildOncogene ProteinsGenetics0303 health sciencesbiologyDNA POOLING ANALYSISPedigree3. Good healthserotoninPsychiatry and Mental healthConduct disorderChild Preschool/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMonoamine oxidase AdopaminePsychologyFunctional Neurogenomics [DCN 2]Genetic MarkersAdolescentSynaptosomal-Associated Protein 25Single-nucleotide polymorphismassociation studyPolymorphism Single NucleotideMental health [NCEBP 9]Genetic determinismGenomic disorders and inherited multi-system disorders [IGMD 3]03 medical and health sciencesCellular and Molecular NeuroscienceMONOAMINE-OXIDASE-ACognitive neurosciences [UMCN 3.2]SDG 3 - Good Health and Well-beingmental disordersmedicineHumansAttention deficit hyperactivity disorderADHDGenetic Predisposition to Disease5-HT1B RECEPTOR GENEddc:610Medizinische Fakultät » Universitätsklinikum Essen » LVR-Klinikum Essen » Klinik für Psychiatrie Psychosomatik und Psychotherapie des Kindes- und JugendaltersMonoamine OxidaseMolecular Biology030304 developmental biologyGenetic associationDopamine Plasma Membrane Transport ProteinsSEROTONIN TRANSPORTER GENEDOPAMINE-BETA-HYDROXYLASESiblingsReceptors Dopamine D4candidate genemedicine.diseaseTwin studyPREFERENTIAL TRANSMISSIONHaplotypesCATECHOL-O-METHYLTRANSFERASEAttention Deficit Disorder with HyperactivityCONDUCT DISORDERbiology.proteinnoradrenalineDEFICIT/HYPERACTIVITY DISORDERNO EVIDENCE030217 neurology & neurosurgerylinkage disequilibriumMolecular Psychiatry
researchProduct